A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS FLY)
September 3, 2026 updated by: UCB Biopharma SRL
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
450
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: UCB Cares
- Phone Number: 001 844 599 2273
Study Contact Backup
- Name: UCB Cares
- Phone Number: 1-844-599-2273
- Email: ucbcares@ucb.com
Study Locations
-
-
-
C.a.b.a, Argentina
- Recruiting
- Sl0044 60004
-
Capital Federal, Argentina
- Recruiting
- Sl0044 60002
-
Córdoba, Argentina
- Recruiting
- Sl0044 60024
-
Mendoza, Argentina
- Recruiting
- Sl0044 60029
-
Quilmes, Argentina
- Recruiting
- Sl0044 60003
-
San Juan, Argentina
- Recruiting
- Sl0044 60011
-
San Miguel de Tucumán, Argentina
- Recruiting
- Sl0044 60014
-
-
-
-
-
Leuven, Belgium
- Recruiting
- Sl0044 40002
-
Liège, Belgium
- Recruiting
- Sl0044 40060
-
-
-
-
-
Québec, Canada
- Recruiting
- Sl0044 50771
-
Rimouski, Canada
- Recruiting
- Sl0044 50259
-
Toronto, Canada
- Recruiting
- Sl0044 50045
-
-
-
-
-
Santiago, Chile
- Recruiting
- Sl0044 60018
-
-
-
-
-
Baotou, China
- Recruiting
- Sl0044 20293
-
Beijing, China
- Recruiting
- Sl0044 20157
-
Beijing, China
- Recruiting
- Sl0044 20173
-
Beijing, China
- Recruiting
- Sl0044 20128
-
Bengbu, China
- Recruiting
- Sl0044 20201
-
Changchun, China
- Recruiting
- Sl0044 20291
-
Changchun, China
- Recruiting
- Sl0044 20342
-
Changsha, China
- Recruiting
- Sl0044 20295
-
Changzhou, China
- Recruiting
- Sl0044 20186
-
Chengdu, China
- Recruiting
- Sl0044 20137
-
Guangzhou, China
- Recruiting
- Sl0044 20019
-
Guangzhou, China
- Recruiting
- Sl0044 20360
-
Guilin, China
- Recruiting
- Sl0044 20290
-
Haikou, China
- Recruiting
- Sl0044 20271
-
Hangzhou, China
- Recruiting
- Sl0044 20296
-
Jinan, China
- Recruiting
- Sl0044 20185
-
Jiujiang, China
- Recruiting
- Sl0044 20364
-
Nanchang, China
- Recruiting
- Sl0044 20192
-
Nanjing, China
- Recruiting
- Sl0044 20024
-
Nanning, China
- Recruiting
- Sl0044 20331
-
Pingxiang, China
- Recruiting
- Sl0044 20272
-
Shanghai, China
- Recruiting
- Sl0044 20172
-
Shanghai, China
- Recruiting
- Sl0044 20020
-
Shantou, China
- Recruiting
- Sl0044 20346
-
Shijiazhuang, China
- Recruiting
- Sl0044 20363
-
Suzhou, China
- Recruiting
- Sl0044 20204
-
Tianjin, China
- Recruiting
- Sl0044 20136
-
Urumuqi, China
- Recruiting
- Sl0044 20275
-
Wenzhou, China
- Recruiting
- Sl0044 20025
-
Wuhan, China
- Recruiting
- Sl0044 20180
-
Wuhan, China
- Recruiting
- Sl0044 20270
-
Xi'an, China
- Recruiting
- Sl0044 20274
-
Xiamen, China
- Recruiting
- Sl0044 20341
-
Yangzhou, China
- Recruiting
- Sl0044 20273
-
Zhengzhou, China
- Active, not recruiting
- Sl0044 20132
-
Zhuzhou, China
- Recruiting
- Sl0044 20361
-
-
-
-
-
Aalborg, Denmark
- Recruiting
- Sl0044 40903
-
Aarhus, Denmark
- Recruiting
- Sl0044 40562
-
Copenhagen, Denmark
- Recruiting
- Sl0044 40513
-
Odense, Denmark
- Recruiting
- Sl0044 40489
-
-
-
-
-
Bordeaux, France
- Recruiting
- Sl0044 40896
-
Le Mans, France
- Recruiting
- Sl0044 40848
-
Montpellier, France
- Recruiting
- Sl0044 40506
-
-
-
-
-
Berlin, Germany
- Recruiting
- Sl0044 40480
-
Cologne, Germany
- Recruiting
- Sl0044 40386
-
Cologne, Germany
- Recruiting
- Sl0044 40716
-
Dessau, Germany
- Withdrawn
- Sl0044 40322
-
Dresden, Germany
- Recruiting
- Sl0044 40356
-
Freiburg im Breisgau, Germany
- Recruiting
- Sl0044 40072
-
Greifswald, Germany
- Recruiting
- Sl0044 40717
-
Herne, Germany
- Recruiting
- Sl0044 40027
-
Jena, Germany
- Recruiting
- Sl0044 40139
-
Leipzig, Germany
- Recruiting
- Sl0044 40078
-
Mainz, Germany
- Recruiting
- Sl0044 40854
-
München, Germany
- Recruiting
- Sl0044 40815
-
Tübingen, Germany
- Recruiting
- Sl0044 40402
-
Vogelsang-gommern, Germany
- Recruiting
- Sl0044 40715
-
-
-
-
-
Athens, Greece
- Recruiting
- Sl0044 40376
-
Athens, Greece
- Recruiting
- Sl0044 40501
-
Heraklion, Greece
- Recruiting
- Sl0044 40377
-
Larissa, Greece
- Recruiting
- Sl0044 40507
-
-
-
-
-
Brescia, Italy
- Recruiting
- Sl0044 40816
-
Genova, Italy
- Recruiting
- Sl0044 40514
-
Milan, Italy
- Recruiting
- Sl0044 40291
-
Milan, Italy
- Recruiting
- Sl0044 40471
-
Padova, Italy
- Recruiting
- Sl0044 40509
-
Pisa, Italy
- Recruiting
- Sl0044 40176
-
Roma, Italy
- Recruiting
- Sl0044 40148
-
Roma, Italy
- Recruiting
- Sl0044 40675
-
Roma, Italy
- Recruiting
- Sl0044 40860
-
Roma, Italy
- Recruiting
- Sl0044 40897
-
Rozzano, Italy
- Recruiting
- Sl0044 40830
-
-
-
-
-
Bunkyō City, Japan
- Recruiting
- Sl0044 20035
-
Bunkyō City, Japan
- Recruiting
- Sl0044 20196
-
Bunkyō City, Japan
- Recruiting
- Sl0044 20279
-
Chūōku, Japan
- Recruiting
- Sl0044 20030
-
Fukuoka, Japan
- Recruiting
- Sl0044 20281
-
Kawagoe, Japan
- Recruiting
- Sl0044 20039
-
Kawasaki-shi, Japan
- Recruiting
- Sl0044 20365
-
Kita-gun, Japan
- Recruiting
- Sl0044 20045
-
Kitakyushu, Japan
- Recruiting
- Sl0044 20065
-
Kurashiki, Japan
- Active, not recruiting
- Sl0044 20301
-
Kyoto, Japan
- Recruiting
- Sl0044 20369
-
Meguro-ku, Japan
- Recruiting
- Sl0044 20069
-
Nagasaki, Japan
- Recruiting
- Sl0044 20071
-
Nagoya, Japan
- Recruiting
- Sl0044 20287
-
Osaka, Japan
- Recruiting
- Sl0044 20368
-
Saga, Japan
- Recruiting
- Sl0044 20084
-
Sagamihara, Japan
- Recruiting
- Sl0044 20283
-
Sapporo, Japan
- Recruiting
- Sl0044 20031
-
Sasebo, Japan
- Recruiting
- Sl0044 20042
-
Sendai, Japan
- Recruiting
- Sl0044 20171
-
Shinjuku-ku, Japan
- Recruiting
- Sl0044 20076
-
Shinjuku-ku, Japan
- Recruiting
- Sl0044 20285
-
Shinjuku-ku, Japan
- Recruiting
- Sl0044 20288
-
Shinjuku-ku, Japan
- Recruiting
- Sl0044 20070
-
Suita, Japan
- Recruiting
- Sl0044 20277
-
Suita-shi, Japan
- Recruiting
- Sl0044 20032
-
Toyoake-shi, Japan
- Recruiting
- Sl0044 20371
-
Tsu, Japan
- Recruiting
- Sl0044 20278
-
Wakayama, Japan
- Recruiting
- Sl0044 20358
-
Yokohama, Japan
- Recruiting
- Sl0044 20370
-
Yoshida-gun, Japan
- Recruiting
- Sl0044 20276
-
-
-
-
-
Cuernavaca, Mexico
- Recruiting
- Sl0044 50250
-
Guadalajara, Mexico
- Recruiting
- Sl0044 50694
-
Mexico City, Mexico
- Recruiting
- Sl0044 50695
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- Sl0044 40838
-
Groningen, Netherlands
- Recruiting
- Sl0044 40292
-
Maastricht, Netherlands
- Recruiting
- Sl0044 40565
-
-
-
-
-
Arequipa, Peru
- Withdrawn
- Sl0044 60026
-
San Juan de Lurigancho, Peru
- Withdrawn
- Sl0044 60008
-
Surco, Peru
- Recruiting
- Sl0044 60009
-
-
-
-
-
Katowice, Poland
- Recruiting
- Sl0044 40398
-
Katowice, Poland
- Recruiting
- Sl0044 40795
-
Krakow, Poland
- Recruiting
- Sl0044 40502
-
Lublin, Poland
- Recruiting
- Sl0044 40037
-
Poznan, Poland
- Recruiting
- Sl0044 40044
-
Poznan, Poland
- Recruiting
- Sl0044 40821
-
Poznan, Poland
- Recruiting
- Sl0044 40484
-
Warsaw, Poland
- Recruiting
- Sl0044 40097
-
Warsaw, Poland
- Recruiting
- Sl0044 40098
-
Wroclaw, Poland
- Recruiting
- Sl0044 40481
-
Wroclaw, Poland
- Recruiting
- Sl0044 40397
-
-
-
-
-
Caguas, Puerto Rico
- Recruiting
- Sl0044 50671
-
San Juan, Puerto Rico
- Recruiting
- Sl0044 50683
-
San Juan, Puerto Rico
- Recruiting
- Sl0044 50767
-
-
-
-
-
Belgrade, Serbia
- Recruiting
- Sl0044 40730
-
Kragujevac, Serbia
- Recruiting
- Sl0044 40466
-
Niška Banja, Serbia
- Recruiting
- Sl0044 40861
-
Novi Sad, Serbia
- Recruiting
- Sl0044 40392
-
-
-
-
-
Busan, South Korea
- Recruiting
- Sl0044 20141
-
Incheon, South Korea
- Recruiting
- Sl0044 20108
-
Seoul, South Korea
- Recruiting
- Sl0044 20104
-
Seoul, South Korea
- Recruiting
- Sl0044 20351
-
Seoul, South Korea
- Recruiting
- Sl0044 20105
-
Suwon, South Korea
- Recruiting
- Sl0044 20092
-
-
-
-
-
A Coruña, Spain
- Recruiting
- Sl0044 40045
-
Badajoz, Spain
- Recruiting
- Sl0044 40826
-
Barcelona, Spain
- Recruiting
- Sl0044 40160
-
Barcelona, Spain
- Recruiting
- Sl0044 40159
-
Castellon, Spain
- Recruiting
- Sl0044 40839
-
Madrid, Spain
- Recruiting
- Sl0044 40857
-
Málaga, Spain
- Recruiting
- Sl0044 40341
-
Mérida, Spain
- Recruiting
- Sl0044 40521
-
Sabadell, Spain
- Recruiting
- Sl0044 40101
-
Santander, Spain
- Recruiting
- Sl0044 40617
-
Santiago de Compostela, Spain
- Recruiting
- Sl0044 40853
-
Seville, Spain
- Recruiting
- Sl0044 40049
-
Seville, Spain
- Recruiting
- Sl0044 40103
-
Seville, Spain
- Recruiting
- Sl0044 40106
-
Vitoria-Gasteiz, Spain
- Recruiting
- Sl0044 40863
-
-
-
-
-
New Taipei City, Taiwan
- Recruiting
- Sl0044 20330
-
Taichung, Taiwan
- Recruiting
- Sl0044 20080
-
Taichung, Taiwan
- Recruiting
- Sl0044 20142
-
Taichung, Taiwan
- Recruiting
- Sl0044 20113
-
Taipei, Taiwan
- Recruiting
- Sl0044 20086
-
Taipei, Taiwan
- Recruiting
- Sl0044 20099
-
Taipei, Taiwan
- Recruiting
- Sl0044 20362
-
Taiyuan, Taiwan
- Recruiting
- Sl0044 20082
-
-
-
-
-
Dubai, United Arab Emirates
- Recruiting
- Sl0044 40908
-
-
-
-
-
Bath, United Kingdom
- Recruiting
- Sl0044 40847
-
Belfast, United Kingdom
- Recruiting
- Sl0044 40858
-
Leeds, United Kingdom
- Recruiting
- Sl0044 40281
-
London, United Kingdom
- Recruiting
- Sl0044 40113
-
Newcastle upon Tyne, United Kingdom
- Recruiting
- Sl0044 40864
-
Sheffield, United Kingdom
- Recruiting
- Sl0044 40701
-
West Bromwich, United Kingdom
- Recruiting
- Sl0044 40725
-
-
-
-
Arizona
-
Avondale, Arizona, United States, 85392
- Recruiting
- Sl0044 50058
-
Chandler, Arizona, United States, 85225
- Recruiting
- Sl0044 50550
-
Gilbert, Arizona, United States, 85297
- Recruiting
- Sl0044 50713
-
Glendale, Arizona, United States, 85306
- Recruiting
- Sl0044 50662
-
Phoenix, Arizona, United States, 85032
- Recruiting
- Sl0044 50052
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- Sl0044 50677
-
-
Arkansas
-
Searcy, Arkansas, United States, 72143
- Recruiting
- Sl0044 50670
-
-
California
-
Beverly Hills, California, United States, 90210
- Recruiting
- Sl0044 50737
-
Beverly Hills, California, United States, 90211
- Recruiting
- Sl0044 50775
-
La Jolla, California, United States, 92037
- Recruiting
- Sl0044 50257
-
La Palma, California, United States, 90623-1730
- Recruiting
- Sl0044 50275
-
Los Alamitos, California, United States, 90720
- Recruiting
- Sl0044 50755
-
Los Angeles, California, United States, 90022
- Recruiting
- Sl0044 50258
-
Menifee, California, United States, 92586
- Recruiting
- Sl0044 50725
-
Orange, California, United States, 92868
- Recruiting
- Sl0044 50340
-
San Leandro, California, United States, 94578
- Recruiting
- Sl0044 50316
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Sl0044 50719
-
-
Florida
-
Brandon, Florida, United States, 33511
- Recruiting
- Sl0044 50239
-
Clearwater, Florida, United States, 33765
- Recruiting
- Sl0044 50630
-
Coral Gables, Florida, United States, 33134
- Recruiting
- Sl0044 50751
-
Gainesville, Florida, United States, 32610
- Recruiting
- Sl0044 50362
-
Hollywood, Florida, United States, 33024
- Recruiting
- Sl0044 50766
-
Margate, Florida, United States, 33063
- Recruiting
- Sl0044 50763
-
Miami, Florida, United States, 33172
- Recruiting
- Sl0044 50681
-
Miami, Florida, United States, 33155
- Recruiting
- Sl0044 50735
-
Miami, Florida, United States, 33126
- Recruiting
- Sl0044 50747
-
Plantation, Florida, United States, 33324
- Recruiting
- Sl0044 50324
-
Tampa, Florida, United States, 33618
- Recruiting
- Sl0044 50698
-
Winter Park, Florida, United States, 32789
- Recruiting
- Sl0044 50585
-
-
Georgia
-
Gainesville, Georgia, United States, 30501-2418
- Recruiting
- Sl0044 50566
-
Marietta, Georgia, United States, 30152
- Recruiting
- Sl0044 50659
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Recruiting
- Sl0044 50699
-
Willowbrook, Illinois, United States, 60527
- Recruiting
- Sl0044 50717
-
-
Indiana
-
New Albany, Indiana, United States, 47150
- Recruiting
- Sl0044 50748
-
-
Iowa
-
Iowa City, Iowa, United States, 52242.
- Recruiting
- Sl0044 50319
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- Sl0044 50074
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202-5700
- Recruiting
- Sl0044 50586
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70836
- Recruiting
- Sl0044 50023
-
Lake Charles, Louisiana, United States, 70605
- Recruiting
- Sl0044 50285
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Sl0044 50660
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Recruiting
- Sl0044 50730
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Sl0044 50219
-
-
Missouri
-
Kansas City, Missouri, United States, 64151
- Recruiting
- Sl0044 50682
-
-
New York
-
Brooklyn, New York, United States, 11201
- Recruiting
- Sl0044 50010
-
Manhasset, New York, United States, 11030
- Recruiting
- Sl0044 50264
-
New York, New York, United States, 10021
- Recruiting
- Sl0044 50077
-
Syracuse, New York, United States, 13210
- Recruiting
- Sl0044 50241
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
- Recruiting
- Sl0044 50238
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Sl0044 50365
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Recruiting
- Sl0044 50001
-
Murfreesboro, Tennessee, United States, 37128
- Recruiting
- Sl0044 50693
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Recruiting
- Sl0044 50738
-
El Paso, Texas, United States, 79902
- Recruiting
- Sl0044 50781
-
Fort Worth, Texas, United States, 76109
- Recruiting
- Sl0044 50673
-
Frisco, Texas, United States, 75035
- Recruiting
- Sl0044 50562
-
Grapevine, Texas, United States, 76051
- Recruiting
- Sl0044 50773
-
Houston, Texas, United States, 77090
- Recruiting
- Sl0044 50696
-
Houston, Texas, United States, 77054
- Recruiting
- Sl0044 50688
-
Houston, Texas, United States, 77090
- Recruiting
- Sl0044 50723
-
Mansfield, Texas, United States, 76063
- Recruiting
- Sl0044 50718
-
Mesquite, Texas, United States, 75150
- Recruiting
- Sl0044 50036
-
-
Washington
-
Spokane Valley, Washington, United States, 99216
- Recruiting
- Sl0044 50061
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Study participant must be ≥16 years of age, (≥18 years of age for China), unless restricted by local regulation, at the time of signing the Informed Consent form (ICF)
Study participants who have moderate to severe disease activity due to either persisting active systemic lupus erythematosus (SLE) or due to an acute worsening of SLE in the scope of frequent relapsing-remitting SLE despite stable standard of care(SOC) medication defined as:
a. Diagnosed with SLE at least 24 weeks before the Screening Visit by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (defined as evidence for anti-dsDNA antibodies in central laboratory) ii) Either complement C3 <lower limit of normal (LLN) OR complement C4 <LLN as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:
- Anti-Smith (anti-Sm) antibodies (central laboratory or source verifiable history)
- Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory)
- Historical evidence for anti-dsDNA antibodies
Anti-ribonucleoprotein (RNP) autoantibodies (central laboratory) d. Moderately to severely active defined as:
- British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND
- Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at the Screening Visit AND
- SLEDAI-2K without labs ≥4 at Baseline Visit e. Receiving the following standard of care (SOC) medications at stable dose:
- Antimalarial treatment in combination with glucocorticoids and/or immunosuppressants or as stand-alone treatment if justified OR
- Treatment with glucocorticoids and/or immunosuppressants if antimalarial treatment is not appropriate (ie, there is documented intolerance in medical history, documented lack of efficacy, contraindications, or lack of availability)
Exclusion Criteria:
- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition
- Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies. This includes systemic reactions due to latex allergy
- Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ (after complete resection [eg, curettage, electrodesiccation] not later than 4 weeks prior to the Screening Visit [V1]), basal cell carcinoma, or dermatological squamous cell carcinoma
- Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
- Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study
- Study participant has clinically significant active or latent infection
- Study participant had a reactivated latent infection (eg, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2) or is currently receiving suppressive therapy for an opportunistic infection
- Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion
- Study participant has used the prohibited medications within the time frame (Wash-Out Period) listed in the Protocol
- Study participant has previously been randomized within this study or has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
- Study participant has participated in another study of an investigational medicinal product (IMP) within the previous 12 weeks or 5 half-lives of the IMP whatever is longer, or is currently participating in another study of an IMP
- Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3g/day, or protein:creatinine ratio >340 mg/mmol at the Screening Visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dapirolizumab pegol
Study participants will receive dapriolizumab pegol throughout the Treatment Period.
|
Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
Other Names:
|
|
Placebo Comparator: Placebo
Study participants will receive placebo throughout the Treatment Period.
|
Study participants will receive placebo at prespecified time-points.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48
Time Frame: Week 48
|
A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b.
No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c.
No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
|
Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Achievement of BILAG 2004 improvement without worsening at Week 48
Time Frame: Week 48
|
BILAG 2004 improvement without worsening can be defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.
|
Week 48
|
|
Achievement of SRI 4 response at Week 48
Time Frame: Week 48
|
The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met):
|
Week 48
|
|
Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48
Time Frame: During Treatment Period up to Week 48
|
A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index. A BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system. Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index. |
During Treatment Period up to Week 48
|
|
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
Time Frame: Week 48
|
Severe BILAG flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index. |
Week 48
|
|
Achievement of LLDAS at Week 40 and maintaining LLDAS at Weeks 44 and 48
Time Frame: Week 40 to Week 48
|
Low lupus disease activity state (LLDAS) is defined as:
|
Week 40 to Week 48
|
|
Change from Baseline to Week 48 in the FATIGUE-PRO Total score
Time Frame: From Baseline to Week 48
|
The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE.
It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31).
The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time.
|
From Baseline to Week 48
|
|
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at Baseline to ≤7.5mg/day at Week 36 and maintained through Week 48
Time Frame: From Baseline to Week 48
|
The achievement of a reduction in glucocorticoid dose from >7.5mg/day prednisone equivalent dose at Baseline to ≤7.5mg/day prednisone equivalent at Week 36 and maintained through Week 48 will be assessed.
|
From Baseline to Week 48
|
|
Change from Baseline in PGA at Week 48
Time Frame: From Baseline to Week 48
|
Physician's Global Assessment of Disease (PGA), the investigator will rate the overall status of the study participant.
The PGA of disease activity used will be a 100 mm linear scale without anchors.
The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease'.
|
From Baseline to Week 48
|
|
Change from Baseline in SLEDAI-2K at Week 48
Time Frame: From Baseline to Week 48
|
SLEDAI-2K measures disease activity.
Disease activity in the 30 days prior to and at the time point of the assessment shall be considered.
It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item.
The total score falls between 0 and 105, with higher scores representing increased disease activity.
|
From Baseline to Week 48
|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Time Frame: From Baseline until Safety Follow-Up (up to Week 54)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
|
From Baseline until Safety Follow-Up (up to Week 54)
|
|
Percentage of participants with serious treatment-emergent adverse events during the study
Time Frame: From Baseline until Safety Follow-Up (up to Week 54)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:
|
From Baseline until Safety Follow-Up (up to Week 54)
|
|
Percentage of participants with treatment-emergent adverse events of special interest during the study
Time Frame: From Baseline until Safety Follow-Up (up to Week 54)
|
An adverse event of special interest is any adverse event (AE) that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
|
From Baseline until Safety Follow-Up (up to Week 54)
|
|
Percentage of participants with treatment-emergent adverse events of special monitoring during the study
Time Frame: From Baseline until Safety Follow-Up (up to Week 54)
|
An adverse event of special monitoring is a product-specific adverse event (AE), adverse reaction, or safety topic considered as requiring special monitoring by UCB.
|
From Baseline until Safety Follow-Up (up to Week 54)
|
|
Change from Baseline in FACIT-Fatigue score at Week 48
Time Frame: From Baseline to Week 48
|
The FACIT (Functional Assessment of Chronic Illness Therapy)-Fatigue scale is a patient-reported outcome (PRO) measure assessing symptoms and impacts of fatigue originally developed in patients with cancer (Cella et al, 2002).
It is composed of 13 items, all scored from 0 (Not at all) to 4 (Very much), and uses a recall period of the past 7 days.
The FACIT-Fatigue score ranges from 0 to 52 with 0 being the worst possible score and 52 being the best possible score (lowest level of fatigue).
To obtain a score from 0 to 52, all negatively worded questions have to be recoded, so that responses range from worst (0) to the best (4) outcome.
|
From Baseline to Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: UCB Cares, 001 844 599 2273 (UCB)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2024
Primary Completion (Estimated)
May 31, 2028
Study Completion (Estimated)
May 31, 2028
Study Registration Dates
First Submitted
September 24, 2024
First Submitted That Met QC Criteria
September 24, 2024
First Posted (Actual)
September 27, 2024
Study Record Updates
Last Update Posted (Actual)
September 4, 2026
Last Update Submitted That Met QC Criteria
September 3, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SL0044
- 2019 (U.S. NIH Grant/Contract: Chief Medical Office (CMO) Alberta Health Services)
- 2023 (U.S. NIH Grant/Contract: GRAMMY Museum Foundation)
- 2019-003407-35 (EudraCT Number)
- 2023-508191-11 (Registry Identifier: EU Clinical Trials)
- U1111-1298-3467 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion.
Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal.
This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD Sharing Time Frame
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.